Fate Therapeutics, Inc.
FATE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $2 | $2 | $2 | $2 |
| % Growth | -8.7% | 17.1% | -12.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $2 | $2 | $2 | $2 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $26 | $27 | $29 | $34 |
| G&A Expenses | $11 | $11 | $14 | $15 |
| SG&A Expenses | $11 | $11 | $14 | $15 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $15 |
| Operating Expenses | $36 | $39 | $43 | $64 |
| Operating Income | -$35 | -$37 | -$41 | -$62 |
| % Margin | -1,995.1% | -1,938.5% | -2,534.1% | -3,319.8% |
| Other Income/Exp. Net | $2 | $3 | $4 | $10 |
| Pre-Tax Income | -$32 | -$34 | -$38 | -$52 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$32 | -$34 | -$38 | -$52 |
| % Margin | -1,852.4% | -1,786.6% | -2,309.5% | -2,803.9% |
| EPS | -0.27 | -0.29 | -0.32 | -0.44 |
| % Growth | 6.9% | 9.4% | 27.3% | – |
| EPS Diluted | -0.27 | -0.29 | -0.32 | -0.44 |
| Weighted Avg Shares Out | 119 | 119 | 118 | 118 |
| Weighted Avg Shares Out Dil | 119 | 119 | 118 | 118 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $3 | $3 | $4 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $3 | $3 | $5 |
| EBITDA | -$29 | -$31 | -$38 | -$42 |
| % Margin | -1,667% | -1,614.7% | -2,329.5% | -2,268.7% |